Inovio Pharmaceuticals Inc (INO)

[mlkrborn]

Inovio Pharma announced earlier Synthetic Avian flu vaccine demonstrates inhibition of multiple H5N1 strains in Phase I trial (INO) 0.57 : Co announced that a single intradermal electroporation boost of its SynCon avian influenza vaccine generated HAI titers against six different, unmatched strains of H5N1 - a distinct new clinical achievement on the global research community's path to develop universal influenza vaccines. This single synthetic vaccine generated a four-fold or greater rise in hemagglutination inhibition titers in 50% of boosted subjects in its Phase I clinical study. In the intramuscular part of the study, VGX-3400X generated antigen-specific antibody and cytotoxic T-lymphocyte responses against all three antigens that the vaccine was encoded to produce. High levels of binding antibodies were observed in 27 of 28 evaluated subjects. After two vaccinations, 13 of 18 vaccinated subjects from the first two cohorts developed strong CTL responses to at least one of the vaccine components. The patients boosted with the minimally invasive ID vaccination have been given a second ID booster vaccination. Additional interim data is expected in 1Q 2012.